Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lilly asserts it will protect Evista rights

Lilly asserts it will protect Evista rights

10th March 2009

Lilly will continue to take all actions required to protect its intellectual property rights for Evista, it has asserted.

These remarks came from the company’s senior vice-president and general counsel Robert A Armitage after it was announced that the firm had been granted a temporary restraining order by Teva to stop the launch of the drug.

Mr Armitage explained he believes Teva’s challenges are “without merit”, adding he expects Lilly to come out triumphantly during the proceedings.

He further noted that the company’s mission is to discover and develop new medicines for patients.

“Respect for our patents is critical to that mission, as is our ability to enforce our patents against those who violate them.”

The medication Evista is intended to be used for the treatment and prevention of osteoporosis and breast cancer in postmenopausal women.

Earlier this month, Lilly’s senior vice-president of human resources Anthony Murphy announced his retirement, which will come into effect from April. His successor will be named at a later date.

The pharmaceutical company was founded in 1876 and is now the tenth largest of its kind in the world.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.